Experimental cell therapy targets tough blood disorder
NCT ID NCT07075484
First seen Mar 04, 2026 · Last updated Jun 13, 2026 · Updated 13 times
Summary
This early-phase study tested a new cell therapy called YTS109 in 7 people with a severe type of autoimmune hemolytic anemia that did not get better after at least 3 other treatments. The therapy uses specially designed immune cells to attack the faulty cells causing the disease. The main goal was to check safety and find the right dose, while also looking at how well it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEMOLYTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute of Hematology & Blood Diseases Hospital, China
Tianjin, Tianjin Municipality, China
Conditions
Explore the condition pages connected to this study.